Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 61 AL 75

Blood-based biomarkers in the anti-amyloid era of Alzheimer's disease: clinical utility, implementation challenges, and future directions

Ho BL, Yang YH.

Neurodegener Dis Manag. 2026 Sep 26:1-17. doi: 10.1080/17582024.2026.2734618. Online ahead of print.

Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies

Pang M, Brothers HM, O'Gorman J, Murphy J, Zabar Y, Lasky T, Shen C, Rubino I, Knopman D.

Alzheimers Dement. 2026 Oct;22(10):e71758. doi: 10.1002/alz.71758.

A positive Alzheimer's blood biomarker is not a diagnosis: the presence-primacy-permission framework for plasma p-tau217

Bhatia V, Khatak A.

Ann Med Surg (Lond). 2026 Sep 8;88(10):6232-6234. doi: 10.1097/MS9.0000000000005661. eCollection 2026 Oct.

Real-world safety and efficacy of lecanemab in the treatment of Alzheimer's disease: a systematic review and meta-analysis

Wu Y, Zhu L, Chen J, Liu J, Yin K, Yang X.

J Neurol. 2026 Oct 21;273(11):675. doi: 10.1007/s00415-026-14224-y.

Real-world clinical, biomarker, and imaging outcomes of lecanemab in Alzheimer's disease: a multicenter longitudinal cohort study in Jiangsu, China

Tang L, Chen X, Zhang L, Fan L, Chen N, Li C, Cai Z, Chen G, Chen H, Ye M, Zheng H, Li Q, Ke Z, Hu Z, Cao M, Yang D, Xu S, Xie C, Li X, Xu X, Yu M, Lian X, Hu H, Li H, Cai X, Chen H, Xu W, Cui G, Zhao Y, Dong J, Zhang L, Zhu X, Zhao H, Xu Y.

Alzheimers Dement. 2026 Oct;22(10):e71936. doi: 10.1002/alz.71936.

Pathway-specific polygenic risk scores modify the association between amyloid and tau PET accumulation in patients with Alzheimer's disease

Valentim C, Denecke J, Frerich S, Betthauser TJ, Li Y, Ahmadi R, Franzmeier N; Alzheimer's Disease Neuroimaging Initiative (ADNI); Malik R, Ewers M.

Alzheimers Dement. 2026 Oct;22(10):e71939. doi: 10.1002/alz.71939.

Pharmacological modulation of cGAS-STING-NLRP3 signaling by nano-immunomodulators in Alzheimer and Parkinson disease

Abdel-Rasol MA.

Inflammopharmacology. 2026 Oct;34(10):6451-6485. doi: 10.1007/s10787-026-02386-0. Epub 2026 Sep 15.

Andrographolide: Mechanisms and Therapeutic Potential in Alzheimer's and Parkinson's Disease

Ríos-Gallardo A, Herrera-Ramirez D, Bastias-Candia S, Inestrosa NC.

Molecules. 2026 Sep 8;31(18):3139. doi: 10.3390/molecules31183139.

Aluminum chloride in Alzheimer's disease: A dual focus on molecular mechanisms and rat experimental models

Khattab NA, El Kadeem A, Goda AE, El-Mahdy NA, El-Shitany N.

Exp Neurol. 2026 Sep;403:115814. doi: 10.1016/j.expneurol.2026.115814. Epub 2026 May 8.

A GPCR atlas across human microglial states in Alzheimer's disease: Insights from snRNA-seq and hiPSC models

Zhang B, Ran Z, Li XY, Wei ZH, Wang DM, Lu MH.

Exp Neurol. 2026 Sep;403:115845. doi: 10.1016/j.expneurol.2026.115845. Epub 2026 May 21.

Recent developments in donepezil-based hybrid molecules as multi-target therapeutics for Alzheimer's disease: A paradigm shift beyond symptomatic treatment

Kumar N, Khan I, Singh J, Kumar K, Kushwaha VK, Ojha S, Raman SK, Shankar G.

Bioorg Chem. 2026 Oct 5;181:110361. doi: 10.1016/j.bioorg.2026.110361. Epub 2026 Aug 10.

Anatomy of a Setback: A Taxonomy of Clinical Trial Failures in Alzheimer's Disease and Strategic Lessons for the Future

Emanuele E, Minoretti P.

FASEB J. 2026 Aug 31;40(16):e72221. doi: 10.1096/fj.202601680RR.

Xanthones and Their Nitrogen and Sulfur Analogs in Alzheimer's Disease: Recent Progress Toward Multifunctional Therapeutics

Malafaia D, Melo L, Silva AMS, Albuquerque HMT.

ChemMedChem. 2026 Aug 27;21(16):e70453. doi: 10.1002/cmdc.70453.

Trehalose's untapped mechanisms in alzheimer's: gut-brain-autophagy signalling beyond the usual targets

Gunasekaran SK, K HKC, Gobinath M, Roychowdhury P, N MS.

Daru. 2026 Aug 31;34(2):65. doi: 10.1007/s40199-026-00647-5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias